SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sahota, S. S. Articles by Stevenson, F. K. Search for Related Content PubMed PubMed Citation Articles by Sahota, S. S. Articles by Stevenson, F. K. Related Collections Neoplasia Oncogenes and Tumor Suppressors Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 95 No. 11 (June 1), 2000: pp. 3534-3540 NEOPLASIA Somatic mutation of bcl-6 genes can occur in the absence of VH mutations in chronic lymphocytic leukemia Surinder S. Sahota, Zadie Davis, Terry J. Hamblin, and Freda K. Stevenson From the Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Southampton, UK.     Abstract Top Abstract Introduction Patients, materials, and... Results Discussion References Somatic mutation in immunoglobulin variable (V) region genes occurs largely in the germinal center and, after neoplastic transformation, imprints V genes of B-cell tumors with the mutational history of the cell of origin. Recently, it has been found that chronic lymphocytic leukemia (CLL) consists of 2 subsets, each with a different clinical course, one with unmutated VH genes consistent with a naive B cell, and the other with mutated VH genes consistent with transit through the germinal center. However, somatic mutation also occurs at another distinct locus, the 5' noncoding region of the bcl-6 gene, in both B-cell tumors and in normal germinal center B cells. To probe the suggestive link between the occurrence of mutations in VH and bcl-6 genes, we analyzed the nature of somatic mutation at these distinct loci in the 2 CLL subsets. Unexpectedly, we found no such link in the CLLs defined by unmutated VH genes, with 4 of 10 cases clearly showing mutations in bcl-6. In those CLLs defined by somatically mutated VH genes, 4 of 9 cases predictively showed bcl-6 mutations. The frequency of bcl-6 mutations was comparable in both subsets, with mutations being biallelic, and in 3 of 8 cases indicative of clonal origins. Surprisingly, intraclonal variation, which is not a feature of VH genes in CLL, was found in 6 of 8 cases in both subsets. These data indicate that somatic mutation of the VH and bcl-6 loci may not necessarily occur in tandem in CLL, suggesting diverse pathways operating on the 2 genes. (Blood. 2000;95:3534-3540) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Patients, materials, and... Results Discussion References V(D)J recombination in precursor B cells is the first step in a multistage process to generate antibody diversity.1 This process generates a unique signature CDR3 sequence that identifies derivative B-cell clones.1,2 After antigen encounter, the V(D)J transcriptional unit is targeted by a potent somatic hypermutation mechanism to generate high-affinity antibody, which occurs by the selection of mutated progeny.3 This process is thought to be largely restricted to the germinal center.1-3 Consequently, analysis of V gene somatic mutation in neoplastic B cells has enabled a characterization of the clonal history of the cell of origin. B-cell tumors have recently been classified in 3 categories: Those with unmutated V genes, in which the cell of origin does not enter the germinal center; those tumors with ongoing V gene mutations, such as follicle center lymphoma (FCL), which arise and remain in the germinal center environment; and tumors with mutated stable V genes, such as multiple myeloma, which have traversed the germinal center and exit, never to return.4 These distinctions have also revealed a significant and clinically relevant division of chronic lymphocytic leukemia (CLL) into 2 subsets, one of which has V-gene sequences in germline configuration, and the other with somatically mutated V genes, a finding independently reported in several studies.5-8 The initial concept that all CLLs arose from a naive B cell clearly had to be revised. In our early study of 22 cases of CLL with the common phenotype of CD5+, CD23+, low-surface immunoglobulin (Ig), we found that unmutated VH genes were associated with atypical morphology and trisomy 12, both features of a less favorable prognosis.8 Expansion of these analyses has confirmed that unmutated V genes, found in approximately 50% of CLLs, are highly associated with a poorer clinical outcome, even at stage A.5 These findings indicate that CLL is derived from B cells arrested at 2 distinct stages of differentiation, with the more mature cell that has encountered the somatic mutation mechanism, being less malignant. In contrast to FCL, however, the mutational pattern in CLL appears stable, with no intraclonal heterogeneity.4-9 It is now known that somatic mutation also targets nonimmunoglobulin loci, to date characterized in the 5'-intronic region of the bcl-6 gene.10 BCL-6 is a proto-oncogene, encoding a transcriptionally active protein with a POZ/Zinc finger motif,11 and maps to chromosome 3q27.12 Its expression regulates germinal center formation and B-cell activity at this site, as well as Th2 T-cell responses.13,14 A high frequency of chromosomal translocations in non-Hodgkin lymphoma, particularly diffuse large-cell lymphoma (DLCL), cluster at band 3q27, specifically at the bcl-6 promoter and first noncoding exon regions, and may lead to deregulated bcl-6 function with a potential role in lymphomagenesis.14-16 Mutations in bcl-6 at this locus also occur in the absence of translocation events, with a target region approximately 2 kilobase (kb) 3' from the transcription initiation site.10 These mutations may be biallelic and are characterized by single point mutations, insertions and deletional events.10,17,18 Single base-point mutations predominate, favoring transitions over transversions,10,17-19 with evidence for strand specificity,18 and although the frequency of mutations in bcl-6 is notably higher than basal rates, in general, it appears to be lower than the frequency of V gene mutations.17,18 Somatic mutation targets both the VH and bcl-6 loci in normal B cells, and is found only in memory and not naive B cells.17-19 In a study at the single cell level, bcl-6 mutation tended to occur in normal B cells containing mutations in their VH genes.17 Although 80% to 100% of these cells displayed mutations in VH, only approximately 30% of the cells had corresponding mutations in bcl-6, implicating differences in targeting of the 2 loci. Bcl-6 mutations also occur in a range of B-cell tumors, and a correlation between mutational status in VH and bcl-6 in B cell has been suggested. However, there were many exceptions, particularly among cases of Burkitt's lymphoma and multiple myeloma.17 Overall, more than half the numbers of germinal centers (GCs) or post-GC cell-derived B-cell tumors studied, which would certainly be expected to harbor VH mutations, did not show mutations in bcl-6.17 Furthermore, GC-resident lymphoma cells characteristically show high levels of intraclonal variation in tumor VH gene sequences, which to date has not been described as a feature of bcl-6 mutations in these tumor cells. Interestingly, this intraclonal variation in bcl-6 sequence has been reported in normal tonsil GC B cells.19 The question that is raised from these findings is whether the same mutational pathway is invariably involved. In this study, we have investigated whether somatic mutation of the bcl-6 gene occurs conjointly with VH mutations in the 2 CLL disease subsets. Previously, Pasqualucci et al17 examined bcl-6 mutations in 33 cases of CLL by SSCP analysis, and a parallel presence of VH and bcl-6 mutations was observed in 5 cases by sequence analysis. Our results from this study suggest distinct routes for VH and bcl-6 mutations in CLL, with ongoing somatic mutations in bcl-6, even in cases with no VH mutations.     Patients, materials, and methods Top Abstract Introduction Patients, materials, and... Results Discussion References Patients Patients with CLL who were analyzed in this report were from 2 cohorts extensively characterized and reported previously.5 Two additional patients (B.P.S. and A.G.) were included in this study, and were assessed clinically and in the laboratory as reported.5 Relevant features and lymphocyte counts are shown in Tables 1 and 2.                                View this table: [in this window] [in a new window]   Table 1. VH genes in patients with chronic lymphocytic leukemia defined by unmutated VH genes                                View this table: [in this window] [in a new window]   Table 2. VH genes in patients with chronic lymphocytic leukemia defined by mutated VH genes Cytogenetics Standard cytogenetic preparations made from whole peripheral blood were analyzed as previously reported.5 Preparation of genomic DNA Whole peripheral blood taken at the time of diagnosis was either used for isolating DNA immediately or stored at 20°C before use. DNA was isolated from 300 µL blood using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI) according to the manufacturer's instructions. Isolated genomic DNA was resuspended in 100 µL of 10 mmol/L Tris HCl, 1 mmol/L EDTA. Amplification of VH genes These methods were reported previously.5 Polymerase chain reaction analysis of -globin and bcl-6 For -globin (G), polymerase chain reaction (PCR) primers were designed to amplify a 724-base pair (bp) fragment of intronic DNA, spanning exons 2 and 3 (GenBank accession no. V00499). The forward G primer was 5'-AGG AAG GGG AGA AGT AAC and the reverse primer was 5'-AAT CCA GCC TTA TCC CAA, each primer used at a final concentration of 400 mmol/L. DNA (5 µL) isolated from patients A.G. and D.B. was amplified using the Advantage-HF2 PCR Kit (Clontech, Hants, UK) in a 50 µL volume and the following PCR conditions: 95°C for 5' (1 cycle), followed by 95°C for 1', 54°C for 1', 72°C for 3' (30 cycles), and 72°C for 10' (1 cycle). Contamination was checked in control reactions with no added template, and stringent working conditions for PCR analysis were used as recommended.20 For amplification of bcl-6 intronic DNA, primers E1.21C and E1.26 described by Migliazza et al10 were used to generate a 732-bp product reported by these authors as a hot-spot region. The same template volume, enzyme system, and PCR conditions used for amplification of G were used. Cloning and sequencing of PCR products Gel-purified PCR products of a predicted size were cloned into the pGEM-TA vector as described and used to transform JM109 competent cells.21 Randomly selected clones found to contain an insert of an appropriate size by restriction analysis of plasmid DNA were sequenced using M13 universal primers, primers used for PCR amplification, or internal primers (bcl-6 sense 5'-AGC AGA GAG GAC GAG ACA GTG CTT; antisense 5'-GAA AAA ACA CAG CCG CAC GAA TCC AGA). Mutations were confirmed by at least 2 separate primers by bidirectional sequencing. Both for VH and bcl-6, a minimum of 4 clones were analyzed per patient. Sequence analysis was carried out using the PCR dye-based dideoxy chain termination method, according to the manufacturer's instructions, and analyzed on an AB Prism 377 sequencer (Perkin-Elmer Applied Biosystems, Warrington, UK). Nucleotide sequences were aligned with GenBank database germline sequences (accession no. Z79581 for bcl-6 intron) using MacVector 4.5.3 software (Scientific Imaging Systems, New Haven, CT).     Results Top Abstract Introduction Patients, materials, and... Results Discussion References Cytogenetic features of patients studied In 18 of 19 patients studied in this report, data were available from karyotype analysis (Tables 1 and 2 and Hamblin et al5), and did not reveal any chromosome 3 abnormality. In our initial cohort of 84 patients with CLL,5 only 2 patients exhibited a karyotype with a chromosome 3 abnormality, del(3)(p21) and t(3;11)(q25:q25), respectively, suggesting a low incidence in the CLL disease. VH analysis in CLL subsets Data showing a clear demarcation of the 2 CLL subsets in a large cohort of 84 patients have been reported previously,5 and are reproduced in part in Tables 1 and 2 for reference. VH gene use by 2 additional patients included in this study (B.P.S. and A.G.) was in germline configuration, and has been deposited in the GenBank/EMBL database (accession no. AJ272398/9). Of note, 4 cases (C.W., D.F., J.B., and N.O.) each showed identical VH sequences in 4 tumor-derived clones. bcl-6 5'-intron sequence In all patients analyzed, a 7-base difference (at positions 607, 769-771, 889, and 987) was observed from the reported germline database sequence (GenBank accession no. Z79581). The first nucleotide of bcl-6 complementary DNA (cDNA) from this reported sequence was arbitrarily chosen as position +1,10 and the amplified bcl-6 5' intronic region spanned +415 to +1140. Taq polymerase error rate In the characterization of bcl-6 mutations in normal and malignant B cells, Pasqualucci et al17 used a 394-bp intron fragment of G to assess Taq misincorporation rate, which was consistently found to be unmutated, indicating that this gene is not targeted for somatic mutation, and is suitable as an internal control to assess bcl-6 mutations. To match the target length of bcl-6 under investigation in this study, a 724-bp fragment of intronic DNA spanning exons 2 and 3 of the G gene was amplified. Subcloning of G PCR DNA and subsequent sequence analysis enabled a quantitation of Taq error rate. For 2 patients (A.G. and D.B.), 15 and 12 clones respectively from the G PCR products were completely sequenced, and 5 mutations were detected in 19 548-bp sequenced, giving a background error rate of 2.6 × 104 bp1 (less than 0.03%). The same PCR amplification conditions were used for bcl-6 analysis. Solely to verify that particular sequence motifs in bcl-6 do not influence the Taq error rate, a bcl-6 clone identified as being unmutated was PCR amplified using the bcl-6 primers and cloned. No mutations were detected in 8 clones sequenced, giving an error rate of less than 1 in 5792 bases (less than 0.02%). bcl-6 polymorphic alleles Two nucleotide changes likely to represent polymorphic variants were observed, a G-C change at position +753 in 16 clones from 5 cases (also described by Migliazza et al10) and a single base deletion (T) at position +875, which was observed in 15 clones from 4 cases (Tables 3, 4, and 5). Polymorphic changes permitted identification of biallelic mutations in bcl-6.                                View this table: [in this window] [in a new window]   Table 3. bcl-6 mutations in chronic lymphocytic leukemia subset defined by unmutated VH gene                                View this table: [in this window] [in a new window]   Table 4. bcl-6 mutations in chronic lymphocytic leukemia subset defined by mutated VH gene                                View this table: [in this window] [in a new window]   Table 5. Comparison of frequency of mutation of bcl-6 and -globin genes in chronic lymphocytic leukemia bcl-6 mutations in CLL The overriding criterion in determining the significance of low levels of bcl-6 mutations is the Taq error rate. Of the CLL cases identified as carrying bcl-6 mutations (Tables 3 and 4), 2 patients, A.G. and D.B., both from the VH unmutated CLL subset, were selected for simultaneous analysis of the frequency of mutations in bcl-6 and -G genes, using identical amounts of template genomic DNA, from the same preparations. It was apparent (Table 5) that in both cases the level of bcl-6 mutation detected was significant, approximately 4-fold higher than the level of Taq misincorporation as assessed by the reference -G gene. This finding was based on a replicate PCR analysis of bcl-6 in these 2 cases (Table 5). As an internal control, replicate PCR analysis of patient A.W. confirmed an absence of mutations in bcl-6 (Table 4), negating any influence of the bcl-6 target gene on Taq error rate at levels present in the isolated genomic DNA in these samples. The analysis of plasmid DNA carrying an unmutated bcl-6 insert, discussed above, confirmed that localized motifs in bcl-6 sequence do not interfere adversely with Taq misincorporation. Consequently, and as a conservative measure, bcl-6 mutations in each case were accepted as significant only when the frequency of mutation was more than 2-fold above the background Taq error rate (Table 5). Using this cutoff value, the incidence of bcl-6 mutations appeared comparable in the 2 disease subsets, with 4 of 10 cases with unmutated VH genes, CLL(UM), and 4 of 9 cases with mutated VH genes, CLL(M), exhibiting bcl-6 mutations (Tables 3 and 4). Overall, 11 of 19 CLL cases showed no mutations in bcl-6 in multiple clones, and this underlines the lack of false positives generated by the PCR cloning and sequencing procedure, as does the detection of polymorphic alleles bearing no other mutations. As in other B-cell tumors, bcl-6 is not targeted for mutation in all CLL cases. The frequency of mutations in the CLL(UM) subset in this study, calculated in those cases displaying bcl-6 mutations, was in the range 6.8 to 12.0 × 104 bp1 with a mean of 9.7 × 104 bp1 appproximately 4-fold higher than the Taq error rate. In the CLL(M) category, in the bcl-6 mutated cases, the frequency was in the range 6.8 to 23.9 × 104 bp1 with a mean of 13.7 × 104 bp1 approximately 6-fold higher than the basal Taq error rate. With respect to the CLL(M) cases, the frequency was comparable to that of bcl-6 mutations (approximately 8 to 20 × 104 bp1) reported in 5 mutated VH CLL cases by Pasqualucci et al.17 By contrast, the frequency of VH gene mutations in the 4 CLL(M) cases in this investigation was 6.7 × 102 bp1 about 50-fold higher than the bcl-6 rate of mutation. The number of bcl-6 mutations per mutated clone from both subsets was in the range 1 to 6 mutations, with the bulk of clones displaying 1 to 3 substitutions (Tables 3, 4, and 5). Overall, a total of 45 distinct mutations were observed, each unique in any given allele. Almost exclusively, these were point mutations (42 of 43). However, mutations included a nucleotide insertion event +G (757) in clone JB1 (Table 4) and a deletion, T (1023) in clone AG25R/2 (Table 3). In 1 CLL(UM) case, 1 mutation was repeated in more than 1 clone: in A.G., clones AG8/1 and AG/25R2 displayed the G-A (756) transition (Table 3). In 2 CLL(M) cases, repeat mutations were also found in separate clones: in C.W., 3 of 4 clones displayed an identical G-A (733) mutation, and in N.O., 2 of 6 clones displayed the same G-C (786) mutation (Table 4). Nature of bcl-6 mutations Single nucleotide substitutions predominated as the type of mutation detected. The overall characteristics of mutational changes are shown in Table 6. There was no apparent difference between the frequency of mutations affecting each base in the 2 subsets (data not shown). The low number of bcl-6 mutations in this study excluded statistical analysis. However, transitions (86%) predominated over transversions (14%), with a preferential bias for T:N over A:N target bases. Each mutation was assessed for influence of flanking bases, and only 2 mutations, G-A (733) in clone CW1 and G-A (721) in clone AG2, occurred in G within an RGYW motif.                                View this table: [in this window] [in a new window]   Table 6. Nature of bcl-6 mutations overall Analysis of intraclonal heterogeneity of bcl-6 mutations To confirm that cloning was a prerequisite to identify low levels of heterogeneous bcl-6 mutations in tumor-derived clones, a mixing experiment was undertaken: 8 clones showing no bcl-6 mutations were mixed with 2 clones showing 2 mutations each in the bcl-6 intron, and the mix PCR amplified. PCR DNA was eluted, and directly sequenced. None of the mutations expected from the 2 parental clones were visible in the resultant chromatogram, confirming the necessity of cloning before bcl-6 sequence analysis. In both categories of CLL, there was evidence for ongoing mutation in bcl-6, clear in all 4 cases (A.G., B.St., D.B., and R.D.) in the CLL(UM) subset, and in 2 of 4 cases (J.B. and N.O.) in CLL(M). In contrast, VH analysis revealed no intraclonal variation in any case, including J.B. and N.O. In all cases, contamination by normal B cells was most likely excluded by high tumor lymphocyte counts (Tables 1 and 2). Indeed, the highest level of variation was observed in the patient (A.G.) with the highest lymphocyte count. To confirm intraclonal heterogeneity, bcl-6 analysis was repeated in 2 cases (A.G. and D.B.), and again, variation was observed in both cases (data not shown), with the higher level again found in patient A.G. Overall, single mutations accounted for most of the mutational differences among multiple tumor-derived clones, with rarer differences of up to 3 mutations, a single base insertion or a doublet mutation also observed. Intraclonal variation in bcl-6 sequence was apparent on both alleles in a number of cases, with each polymorphic allele displaying a variable level of mutation within each individual case.     Discussion Top Abstract Introduction Patients, materials, and... Results Discussion References The price of somatic mutation in immunoglobulin V genes of B cells, so essential for the development of high-affinity antibodies, is the danger of exposing the genome to potentially damaging mutation in other genes. Generally, it appears that control of the mechanism is tight and that extraneous mutation is rare. However, recent findings on the bcl-6 gene have revealed nucleotide changes, and it has been suggested that this gene may be a target for the same mutational process. This has been supported by the finding that mutations in bcl-6 tend to be more common in B cells, both normal and neoplastic, which have encountered the germinal center environment, where somatic mutation in V genes occurs.1-3 Data on the incidence and distribution of somatic mutations in candidate genes clearly depend on the material used and the technology applied. For a gene such as bcl-6, the level of mutation described can vary, with frequencies in the range of 7 × 104 bp1 to 1.6 × 102 bp1.17 The preliminary indication was that in all 5 CLL(M) displaying bcl-6 mutations, the frequency is at the lowest end of this range, approximately 8 to 20 × 104 bp1.17 These mutations are found only in a small number of CLL cases, with over 70% showing no mutations in bcl-6.17,22 A paramount requirement therefore, given the expected low level of bcl-6 mutations in CLL, is to distinguish such mutations from sequencing error. For our study, this error rate was stringently documented using a relevant control gene within each selected sample: two cases of CLL(UM), A.G. and D.B., which unexpectedly showed bcl-6 mutations, did so in a background of low Taq error as judged by the frequency of G mutations in an identical amount of template genomic DNA. A number of cases, using this stringency of assay, were not mutated in bcl-6, and this was verified by repeat PCR in 1 case, showing that Taq catalysis did not introduce extraneous mutations given the level of target bcl-6 gene present in these DNA preparations. Any possible bias introduced by localized bcl-6 motifs was also excluded. The second point to recognize is polymorphic changes in the bcl-6 locus, some, but possibly not all of which have been described.10,17 Thirdly, it is highly desirable to have a homogeneous tumor population to avoid contamination with other B cells that carry mutations. For CLL, the material consists of tumor cells at high count obtained from blood. Because the cases are generally more than 98% tumor cells, the possibility of contamination with normal B cells is negligible. We chose to use PCR amplification and cloning to investigate bcl-6 mutations, partly because of the higher sensitivity, but also because this allows analysis of intraclonal variation, as verified by the mixing experiment. This phenomenon is a feature of VH genes in B-cell tumors of the germinal center,4 and has also been suggested in bcl-6 genes of normal B cells.19 Intraclonal variation would be difficult to detect to a comparable degree by SSCP analysis. We were also able to exclude in this study any association between the translocation status of the bcl-6 gene and the incidence of bcl-6 mutations, as all the cases studied were free of this specific chromosomal abnormality. This observation in CLL extends findings in FCL and DLCL,10 where somatic mutation of bcl-6 genes has been shown to occur independently of any chromosomal rearrangement. After careful assessment of the Taq error rate and elimination of recurrent changes, considered to be polymorphic variation, from the analysis, we were able to identify somatic mutations in bcl-6 in 8 of 19 cases of CLL. Surprisingly, these were not only in the cases with mutated VH genes, but were also found in 4 of 10 of those cases with no mutations in VH. The other unexpected feature was that intraclonal variation in bcl-6 was evident in 6 of the 8 mutated cases. The heterogeneity appeared to be quite wide, with only 3 cases (C.W., N.O., and A.G.) showing the same mutation in more than 1 clone. One of these (A.G.) was a CLL(UM) case. Clearly, these repeated mutations in separate clones again argue against origins by Taq error, and point to subdominant clonal populations. Not all clones in the CLL(UM) cases exhibit bcl-6 mutations, and this might explain the low number of cases of CLL with mutations detected by SSCP analysis.17 In those cases in which no mutations were detected in our study, it remains possible that analysis of more than 4 clones is required to detect bcl-6 changes, and to establish whether these cases are truly negative for bcl-6 mutations. It is known that intraclonal heterogeneity in VH is extremely rare in CLL, as this is a tumor that does not reside in the germinal center.4-9 Because intraclonal heterogeneity was not found in the VH genes of the cases with heterogeneity in bcl-6, it suggests that the mutation mechanism may operate differently on the 2 loci. Indeed, it may prove to be the case that the dislocation of somatic mutation at the VH and bcl-6 loci is a feature peculiar to CLL. It is noteworthy here that somatic mutation of VL occurs in parallel to VH in CLL tumor cells.9 These observations raise important questions regarding current concepts of bcl-6 mutations in normal and malignant B cells. First, where do the bcl-6 mutations observed at a significant level in CLL(UM) cases, originating from naive B-cell precursors, arise, and is the same mechanism involved? Second, our data indicate that CLL cases are continually undergoing such mutations after transformation, some of which are detected as clonal mutations. These findings may not exclude a coupled mechanism targeting VH and bcl-6 mutations in CLL(M) cases, but suggest ongoing mutations at the bcl-6 locus alone. To date, analysis of bcl-6 mutations by PCR and cloning in DLCL suggest that there is no significant ongoing mutations in these cases.10 The inference is that the bcl-6 mutations in DLCL arose before neoplastic transformation, and that this locus is not targeted in tumor cells. Our observations suggest that other features of bcl-6 mutations, in addition to those currently described, may exist. Interestingly, preliminary observations of intraclonal variation in bcl-6 mutations have recently been reported, both in non-Hodgkin lymphoma,23 and in highly purified multiple myeloma plasma cells.24 In addition, intraclonal sequence variation of the bcl-6 gene has been observed in normal tonsil GC B cells.19 The frequency of bcl-6 mutations in CLL, and the predominance of point mutations favoring transitions, together with an apparent lack of an A-N strand bias are features comparable to other diverse lymphoid malignancies.17,19 Differences exist in that a T-N bias was detected, and a lack of an RGYW motif dependence of bcl-6 mutations; however, the number of cases analyzed preclude any statistical evaluation. Mutations at the VH locus, or their absence, are a significant prognostic feature in the CLL disease, but bcl-6 mutations in the 2 subsets do not apparently correlate with the prognosis. This is in contrast to posttransplantation lymphoproliferative disorders in which bcl-6 mutations have been found to have a predictive relevance to disease outcome.25 Analysis of bcl-6 rearrangements in DLCL have proved a useful prognostic marker,26 whereas bcl-6 mutational status did not correlate with prognostic significance in DLCL of primary gastric origin.27 It has been proposed that intronic mutations in the bcl-6 gene may have a role in lymphomagenesis.17,28 There are preliminary indications of these mutations leading to altered binding of regulatory proteins,29 and of defective Bcl-6 protein activity,28 but clearly the nature of the mutations and their affect on gene expression could be crucial. For CLL, Bcl-6 protein expression has not been detected,30,31 and the role of the mutations in the noncoding region are so far unknown. It is apparent that in a large number of malignant B-cell cases, including CLL, the bcl-6 gene remains unchanged. Evidently mutations in bcl-6 are not a requirement for development of CLL, but it will be of interest to probe further into the involvement, if any, of this gene in the pathology of CLL.     Acknowledgment We would like to thank Dr Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy, for useful discussions.     Footnotes Submitted August 17, 1999; accepted February 3, 2000. Supported by The Leukaemia Research Fund and Tenovus UK. Reprints: Surinder S. Sahota, Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Tremona Rd, Southampton SO16 6YD, UK; email: sss1{at}soton.ac.uk. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Patients, materials, and... Results Discussion References 1. Honjo T,Alt FW, eds. Immunoglobulin Genes. 2nd ed. London, UK: Academic Press; 1995. 2. Berek C. The development of B cells and the B cell repertoire in the microenvironment of the germinal centre. Immunol Rev. 1992;126:5-19[Medline] [Order article via Infotrieve]. 3. Steele EJ, ed. Somatic Hypermutation in V-regions. Boca Raton, FL: CRC Press; 1991. 4. Stevenson F, Sahota S, Zhu D, et al. Insight into the origin and clonal history of B-cell tumours as revealed by analysis of immunoglobulin variable region genes. Immunol Rev. 1998;162:247-259[Medline] [Order article via Infotrieve]. 5. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated immunoglobulin VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1-8[Abstract/Free Full Text]. 6. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847[Abstract/Free Full Text]. 7. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525[Medline] [Order article via Infotrieve]. 8. Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in VH genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood. 1997;89:4153-4160[Abstract/Free Full Text]. 9. Schettino EW, Cerutti A, Chiorazzi N, Casali P. Lack of intraclonal diversification in Ig heavy and light chain V region genes expressed by CD5+IgM+ chronic lymphocytic leukemia B cells: a multiple time point analysis. J Immunol. 1998;160:820-830[Abstract/Free Full Text]. 10. Migliazza A, Martinotti S, Chen W, et al. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A. 1995;92:12,520-12,524[Abstract/Free Full Text]. 11. Bardwell VJ, Treisman R. The POZ domain: a conserved protein-protein interaction motif. Genes Dev. 1994;8:1664-1677[Abstract/Free Full Text]. 12. Ye BH, Rao PH, Chaganti RS, Dalla-Favera R. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res. 1993;53:2732-2735[Abstract/Free Full Text]. 13. Catoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood. 1995;86:45-53[Abstract/Free Full Text]. 14. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16:161-170[Medline] [Order article via Infotrieve]. 15. Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science. 1993;262:747-750[Abstract/Free Full Text]. 16. Ye BH, Chaganti S, Chang C-C, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J. 1995;14:6209-6217[Medline] [Order article via Infotrieve]. 17. Pasqualucci L, Migliazza A, Fracchiolla N, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A. 1998;95:11,816-11,821[Abstract/Free Full Text]. 18. Shen HM, Peters A, Baron B, Zhu X, Storb U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutations of Ig genes. Science. 1998;280:1750-1752[Abstract/Free Full Text]. 19. Peng H-Z, Du M-Q, Koulis A, et al. Nonimmunoglobulin gene hypermutation in germinal center B cells. Blood. 1999;93:2167-2172[Abstract/Free Full Text]. 20. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature. 1989;339:237-238[Medline] [Order article via Infotrieve]. 21. Sahota SS, Leo R, Hamblin TJ, Stevenson FK. Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood. 1996;87:746-755[Abstract/Free Full Text]. 22. Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood. 2000;95:651-659[Abstract/Free Full Text]. 23. Lossos IS, Levy R. Mutation analysis of the 5' noncoding regulatory region of the bcl-6 gene in non-Hodgkin's lymphoma: evidence for intraclonal heterogeneity. Blood. 1999;94(suppl 1):58a. 24. Rothwell DG, Kalakonda N, Scarffe JH, Norton JD. Tumour cell population dynamics in multiple myeloma: analysis of N-Ras and Bcl-6 mutations. Blood. 1999;94(suppl 1):543a. 25. Cesarman E, Chadburn A, Liu Y-F, Migliazza A, Dalla-Favera R, Knowles DM. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood. 1998;92:2294-2302[Abstract/Free Full Text]. 26. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the BCL6 gene as a prognostic marker in diffuse large cell lymphoma. N Engl J Med. 1994;331:74-80[Abstract/Free Full Text]. 27. Liang R, Chan WP, Kwong YL, et al. BCL-6 gene hypermutations in diffuse large B-cell lymphoma of primary gastric origin. Br J Haematol. 1997;99:668-670[Medline] [Order article via Infotrieve]. 28. Gaidano G, Carbone A, Pastore C, et al. Frequent mutation of the 5' noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood. 1997;89:3755-3762[Abstract/Free Full Text]. 29. Nakamura Y, Saito K, Furusawa S. Analysis of internal deletions within the BCL6 gene in B-cell non-Hodgkin's lymphoma. Br J Haematol. 1999;105:274-277[Medline] [Order article via Infotrieve]. 30. Flenghi L, Bigerna B, Fizzotti M, et al. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. Am J Pathol. 1996;48:1543-1555. 31. Falini B, Fizzotti M, Pileri S, Liso A, Pasqualucci L, Flenghi L. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol. 1997;8(suppl 2):101-104[Free Full Text]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Kotani, N. Kakazu, T. Tsuruyama, I.-m. Okazaki, M. Muramatsu, K. Kinoshita, H. Nagaoka, D. Yabe, and T. Honjo Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice PNAS, January 30, 2007; 104(5): 1616 - 1620. [Abstract] [Full Text] [PDF] M. F. Rosado, G. E. Byrne Jr, F. Ding, K. A. Fields, P. Ruiz, S. R. Dubovy, G. R. Walker, A. Markoe, and I. S. Lossos Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci Blood, January 15, 2006; 107(2): 467 - 472. [Abstract] [Full Text] [PDF] B. T. Messmer, E. Albesiano, D. Messmer, and N. Chiorazzi The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process Blood, May 1, 2004; 103(9): 3490 - 3495. [Abstract] [Full Text] [PDF] A. Guarini, G. Gaidano, F. R. Mauro, D. Capello, F. Mancini, M. S. De Propris, M. Mancini, E. Orsini, M. Gentile, M. Breccia, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features Blood, August 1, 2003; 102(3): 1035 - 1041. [Abstract] [Full Text] [PDF] S. A. Pileri, G. Gaidano, P. L. Zinzani, B. Falini, P. Gaulard, E. Zucca, F. Pieri, E. Berra, E. Sabattini, S. Ascani, et al. Primary Mediastinal B-Cell Lymphoma: High Frequency of BCL-6 Mutations and Consistent Expression of the Transcription Factors OCT-2, BOB.1, and PU.1 in the Absence of Immunoglobulins Am. J. Pathol., January 1, 2003; 162(1): 243 - 253. [Abstract] [Full Text] [PDF] A. Cerutti, H. Zan, E. C. Kim, S. Shah, E. J. Schattner, A. Schaffer, and P. Casali Ongoing In Vivo Immunoglobulin Class Switch DNA Recombination in Chronic Lymphocytic Leukemia B Cells J. Immunol., December 1, 2002; 169(11): 6594 - 6603. [Abstract] [Full Text] [PDF] C. Gurrieri, P. McGuire, H. Zan, X.-J. Yan, A. Cerutti, E. Albesiano, S. L. Allen, V. Vinciguerra, K. R. Rai, M. Ferrarini, et al. Chronic Lymphocytic Leukemia B Cells Can Undergo Somatic Hypermutation and Intraclonal Immunoglobulin VHDJH Gene Diversification J. Exp. Med., September 2, 2002; 196(5): 629 - 639. [Abstract] [Full Text] [PDF] N. Welzel, T. Le, R. Marculescu, G. Mitterbauer, A. Chott, C. Pott, M. Kneba, M.-Q. Du, R. Kusec, J. Drach, et al. Templated Nucleotide Addition and Immunoglobulin JH-Gene Utilization in t(11;14) Junctions: Implications for the Mechanism of Translocation and the Origin of Mantle Cell Lymphoma Cancer Res., February 1, 2001; 61(4): 1629 - 1636. [Abstract] [Full Text] L. Pasqualucci, A. Neri, L. Baldini, R. Dalla-Favera, and A. Migliazza BCL-6 Mutations Are Associated with Immunoglobulin Variable Heavy Chain Mutations in B-Cell Chronic Lymphocytic Leukemia Cancer Res., October 1, 2000; 60(20): 5644 - 5648. [Abstract] [Full Text] C. H. Ottensmeier and F. K. Stevenson Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma Blood, October 1, 2000; 96(7): 2550 - 2556. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sahota, S. S. Articles by Stevenson, F. K. Search for Related Content PubMed PubMed Citation Articles by Sahota, S. S. Articles by Stevenson, F. K. Related Collections Neoplasia Oncogenes and Tumor Suppressors Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020